Patents by Inventor Taro Semba

Taro Semba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11083705
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 10, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Publication number: 20210177802
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Publication number: 20210023047
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof
    Type: Application
    Filed: March 31, 2020
    Publication date: January 28, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Publication number: 20200199689
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20170191137
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Patent number: 8772269
    Abstract: The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: July 8, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba
  • Publication number: 20140148483
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 29, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20100291592
    Abstract: The sensitivity of a tumor cell to a sulfonamide compound or the anti-tumor effect of a sulfonamide compound can be examined by determining the expression level of EGFR1 in the tumor cell and employing the variation in the EGFR1 expression level as a measure. Thus, a method for determination of the sensitivity of a tumor cell to a sulfonamide compound; a method for determination of the anti-tumor effect of a sulfonamide compound; and a test kit for use in these methods are provided.
    Type: Application
    Filed: April 20, 2007
    Publication date: November 18, 2010
    Inventor: Taro Semba
  • Patent number: 7834049
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: November 16, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20100267754
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Application
    Filed: June 10, 2010
    Publication date: October 21, 2010
    Inventors: Toshiaki WAKABAYASHI, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20100105031
    Abstract: Disclosed is a method for the prediction of the efficacy of a vascularization inhibitor. In the method, the anti-tumor effect of a vascularization inhibitor can be predicted by measuring the number of blood vessels surrounded by pericytes in a tumor and using the measurement value as a measure for the anti-tumor effect.
    Type: Application
    Filed: August 1, 2006
    Publication date: April 29, 2010
    Applicant: Esai R & D Management Co., Ltd.
    Inventors: Junji Matsui, Taro Semba
  • Publication number: 20090269352
    Abstract: The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor/FGF inhibitor.
    Type: Application
    Filed: July 6, 2009
    Publication date: October 29, 2009
    Inventors: Toshiaki WAKABAYASHI, Naoto Ono, Taro Semba, Toru Haneda
  • Publication number: 20090047365
    Abstract: The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.
    Type: Application
    Filed: February 28, 2006
    Publication date: February 19, 2009
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Naoko Hata
  • Publication number: 20090047278
    Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity.
    Type: Application
    Filed: February 28, 2006
    Publication date: February 19, 2009
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Toshiaki Wakabayashi
  • Publication number: 20080286282
    Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.
    Type: Application
    Filed: February 28, 2006
    Publication date: November 20, 2008
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Taro Semba, Naoko Hata, Yoichi Ozawa, Takashi Owa
  • Publication number: 20060135486
    Abstract: The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.
    Type: Application
    Filed: September 13, 2005
    Publication date: June 22, 2006
    Applicant: Eisai Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba
  • Publication number: 20050176712
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Application
    Filed: April 4, 2005
    Publication date: August 11, 2005
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20050119303
    Abstract: The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor/FGF inhibitor.
    Type: Application
    Filed: March 4, 2003
    Publication date: June 2, 2005
    Applicant: EISAI CO., LTD
    Inventors: Toshiaki Wakabayashi, Naoto Ono, Taro Semba, Toru Haneda
  • Patent number: 6787534
    Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: September 7, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
  • Publication number: 20040018192
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 29, 2004
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda